Document Detail


Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
MedLine Citation:
PMID:  11940547     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Intravenous recombinant tissue plasminogen activator (rtPA) is an effective therapy for acute ischemic stroke, but it is associated with risk of intracerebral hemorrhage (ICH). Our aim was to identify, in a large cohort of patients, readily available baseline factors that are associated with thrombolysis-related ICH. METHODS AND RESULTS: In a multicenter retrospective and prospective investigation of individual data from 1205 patients treated in routine clinical practice with intravenous rtPA within 3 hours of stroke symptom onset, 72 patients (6%) developed symptomatic ICH and 86 additional patients (7%) had asymptomatic ICH identified on a routine follow-up CT. In analyses based on clinical variables alone, the main attributes associated with ICH were a history of diabetes mellitus and cardiac disease, increasing stroke severity, advancing age, use of antiplatelet agents other than aspirin before stroke onset, and elevated pretreatment mean blood pressure. In additional analyses that incorporated baseline CT and laboratory findings (in a subset of patients), the main associations were early ischemic CT changes, in particular if exceeding one third of middle cerebral artery territory; increasing stroke severity; diabetes mellitus or elevated serum glucose; and lower platelet counts. Final independent attributes associated with parenchymatous hematoma, defined by purely radiologically based criteria, were similar to those of symptomatic ICH. CONCLUSIONS: Readily available factors can identify acute ischemic stroke patients at high and low risk for rtPA-related ICH. These factors require confirmation in a prospective cohort before clinical implementation.
Authors:
David Tanne; Scott E Kasner; Andrew M Demchuk; Nira Koren-Morag; Sandra Hanson; Martin Grond; Steven R Levine
Related Documents :
8673957 - Reciprocal inhibition in hemiplegia: correlation with clinical features and recovery.
8123877 - Ischemic stroke in congenital (type ii c) defective antithrombin iii.
19264737 - Basal ganglia and internal capsule stroke in childhood--risk factors, neuroimaging, and...
10512247 - Comparison of transcranial color-coded duplex sonography and cranial ct measurements fo...
19916707 - Contribution of impaired mobility to patient burden in multiple sclerosis.
23987917 - Hematologic and bone marrow changes in children with protein-energy malnutrition.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  105     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2002 Apr 
Date Detail:
Created Date:  2002-04-09     Completed Date:  2002-04-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1679-85     Citation Subset:  AIM; IM    
Affiliation:
Stroke Unit, Department of Neurology, Chaim Sheba Medical Center, Tel Hashomer, Israel. tanne@post.tau.ac.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Biological Markers / blood*
Brain Ischemia / blood*,  complications,  diagnosis
Canada
Cerebral Hemorrhage / diagnosis,  etiology,  prevention & control*
Cohort Studies
Female
Germany
Humans
Injections, Intravenous
Logistic Models
Male
Middle Aged
Models, Cardiovascular
ROC Curve
Recombinant Proteins / administration & dosage,  adverse effects
Risk
Risk Assessment
Stroke / blood*,  complications,  diagnosis
Survival Rate
Tissue Plasminogen Activator / administration & dosage,  adverse effects*
Tomography, X-Ray Computed
United States
Grant Support
ID/Acronym/Agency:
K23-NS02147/NS/NINDS NIH HHS; R01-NS30896/NS/NINDS NIH HHS; T32-NS07412/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Recombinant Proteins; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections
Comment In:
Circulation. 2002 Apr 9;105(14):e9094-5   [PMID:  11940564 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II b...
Next Document:  Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal ...